A promising vaccine against the Bundibugyo strain is emerging, with several institutions already working on clinical trials. In response to the ongoing Ebola Bundibugyo virus outbreak in the Democratic Republic of Congo, the Oxford Vaccine Group (OVG) is working closely with its own clinical bioproduction center and the Serum Institute of India Pvt. Ltd. (SIIPL) to rapidly produce and scale up production of its monovalent vaccine candidate against the Ebola Bundibugyo virus, ChAdOx1 BDBV, based on ChAdOx technology. In parallel, we are collaborating with our international partners to accelerate the generation of preclinical data essential for the clinical development and trials of the ChAdOx1 BDBV vaccine in an epidemic setting, while strictly adhering to applicable scientific, ethical, and regulatory standards.
No comments:
Post a Comment